HC Wainwright Reiterates “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

HC Wainwright restated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research note released on Monday morning,Benzinga reports. They currently have a $25.00 target price on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2028 earnings at $0.43 EPS and FY2029 earnings at $1.81 EPS.

Milestone Pharmaceuticals Trading Down 16.4 %

Shares of MIST stock opened at $1.99 on Monday. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average price of $2.02 and a two-hundred day moving average price of $1.81. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75. The firm has a market cap of $106.12 million, a P/E ratio of -2.46 and a beta of 1.83.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp increased its holdings in shares of Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after buying an additional 10,000 shares during the period. National Bank of Canada FI increased its holdings in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares during the period. Atria Investments Inc increased its holdings in shares of Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after buying an additional 12,430 shares during the period. PVG Asset Management Corp purchased a new position in shares of Milestone Pharmaceuticals in the third quarter worth about $46,000. Finally, Northern Trust Corp increased its holdings in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after buying an additional 30,772 shares during the period. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.